Intravitreal Avastin® (bevacizumab) for Refractory Pseudophakic CME: Pan-American Collaborative Retina Study Group Results at 12 months
July 1, 2009
In an article published online in the journal Ophthalmology, researchers evaluated the effectiveness, feasibility and safety of intravitreal Avastin® (bevacizumab, Genentech, Inc., San Francisco, CA) in patients with refractory pseudophakic CME over a 24 month period.
The researchers followed 36 eyes of 31 patients in an interventional, retrospective, multicenter study. Each patient received at least one injection of bevacizumab and the BCVA and central macular thickness as measured by OCT were examined. Seventy-two percent of the eyes demonstrated an improvement of BCVA and the mean central macular thickness had decreased significantly at 12 months. The average number of injections was 2.7.
There were no ocular or systemic adverse events noted.
Read the entire article here (login required).
Jump down to form below to submit your own comments